ArticleOphthalmology and therapy2026
Prognostic Imaging Biomarkers in Diabetic Macular Edema Treated with Anti-VEGF: A Multicenter AI Perspective.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to identify optical coherence tomography (OCT) biomarkers at baseline and after the loading phase (LP) of antivascular endothelial growth factor (VEGF), predictive of 12 months (12 m) morpho-functional outcomes in diabetic macular edema (DME).
methodsThis multicenter, retrospective study involved treatment-naive DME eyes treated with anti-VEGF agents. The OCT volume scans at baseline, after the LP, and at 12 m were analyzed by an artificial intelligence (AI)-derived platform (Discovery OCT Biomarker Detector; RetinAI AG, Bern, Switzerland). Different retinal layer thicknesses and volumes, intraretinal fluid (IRF), subretinal fluid (SRF), and biomarkers probability detection, including hyperreflective foci (HF) were measured. A random forest model assessed the predictive factors for final morphological and functional outcomes.
resultsA total of 77 treatment-naive DME eyes from 64 patients treated with anti-VEGF (88.3% aflibercept, 11.7% ranibizumab; mean n. of injections 9.93 ± 3.18) were enrolled. A significant reduction of all the retinal layers, IRF, SRF, and retinal volumes (p < 0.05) after the LP and at 12 m was found. The random forest model revealed that a higher baseline IRF volume was a moderate predictor and a lower outer nuclear layer (ONL) thickness after LP was a strong predictor for a good morphological response at 12 m. Best-corrected visual acuity (BCVA) prediction remained limited due to weaker associations with OCT biomarkers.
conclusionsAI-derived software showed promise in detecting OCT biomarkers and improving 1-year outcome prediction in DME management. Baseline IRF volume and ONL thickness after the LP were strong predictors of achieving a structural response at 12 m, with overall good model performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.